MIM
CTNM

Monashee Investment Management’s Contineum Therapeutics CTNM Stock Holding History

Monashee Investment Management’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-137,430
Closed -$1.57M – 61
2025
Q4 		$1.57M Buy
+137,430
New +$1.57M 0.89% 32

Other funds holding CTNM

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Monashee Investment Management's CTNM Position: Q1 2026 in Review

Monashee Investment Management sold out of Contineum Therapeutics (CTNM) in Q1 2026, closing a stake of 137,430 shares — an estimated $1.57M sold.

Monashee Investment Management first reported a position in CTNM in Q4 2025 and held it in 1 quarter. The position peaked at $1.57M in Q4 2025. 90 funds tracked by Wall St. Rank hold CTNM as of Q1 2026.

  • Monashee Investment Management reported no remaining Contineum Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Monashee Investment Management sold 137,430 Contineum Therapeutics shares in Q1 2026, an estimated $1.57M.
  • Monashee Investment Management first reported a position in Contineum Therapeutics in Q4 2025 and held it in 1 quarter.
  • Monashee Investment Management's Contineum Therapeutics position peaked at $1.57M in Q4 2025.
  • 90 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q1 2026.

Based on Monashee Investment Management's 13F filing for Q1 2026, filed 13 May 2026.